{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:51:34Z","timestamp":1761173494630,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.purol.2012.12.010","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T22:18:45Z","timestamp":1359670725000},"page":"336-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Traitement d\u2019entretien par BCG-th\u00e9rapie des tumeurs de vessie n\u2019infiltrant pas le muscle (TVNIM)\u00a0: r\u00e9sultats \u00e0 un an de l\u2019\u00e9tude multicentrique URO-BCG-4"],"prefix":"10.1016","volume":"23","author":[{"given":"I.","family":"Galliot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Le Gall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rigaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Saint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wallerand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Fantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Staerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Soulie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl.\u00a04","key":"10.1016\/j.purol.2012.12.010_bib0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1166-7087(10)70043-9","article-title":"Recommandations 2010\u20132013\u00a0en onco-urologie\u00a0: tumeurs uroth\u00e9liales","volume":"20","author":"Pfister","year":"2010","journal-title":"Prog Urol"},{"issue":"15","key":"10.1016\/j.purol.2012.12.010_bib0010","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.purol.2012.05.002","article-title":"Recommandations du Comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie (CCAFU) pour la bonne pratique des instillations endo-v\u00e9sicales de BCG et de mitomycine\u00a0C dans le traitement des tumeurs de vessie n\u2019envahissant pas le muscle (TVNIM)","volume":"22","author":"Roupret","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin\u00a0C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1\u00a0and carcinoma in situ transitional cell carcinoma of the bladder: a randomized South West Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)49690-X","article-title":"Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer","volume":"132","author":"Morales","year":"1984","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0090-1229(86)90043-7","article-title":"Interleukin-2\u00a0production during intravesical bacille Calmette-Guerin therapy for bladder cancer","volume":"40","author":"Ratliff","year":"1986","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.purol.2012.12.010_bib0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.purol.2012.12.010_bib0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(85)90169-2","article-title":"Systemic complications of intravesical BCG therapy for bladder cancer","volume":"2","author":"Steg","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.purol.2012.12.010_bib0055","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.purol.2012.12.010_bib0060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.eururo.2008.06.062","article-title":"Is maintenance bacillus Calmette-Gu\u00e9rin really necessary?","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0065","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.purol.2012.12.010_bib0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000475204","article-title":"Improving the efficacy of BCG immunotherapy by dose reduction","volume":"27","author":"Pagano","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2012.12.010_bib0080","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin\u00a0C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0085","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eursup.2006.04.008","article-title":"Improving patients outcomes: optimal BCG treatment regimen to prevent progression in superficial cancer","volume":"5","author":"Lamm","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0090","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Guerin in intermediate and high risk Ta, T1\u00a0papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1year versus 3years of maintenance","author":"Odden","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0095","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.urology.2008.12.039","article-title":"Discontinuance of bacillus Calmette-Guerin instillation therapy for non muscle-invasive bladder cancer has negative effect on tumor recurrence","volume":"73","author":"Takeda","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.purol.2012.12.010_bib0100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cncr.23627","article-title":"Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough?","volume":"113","author":"Decobert","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.purol.2012.12.010_bib0105","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","article-title":"Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group","volume":"75","author":"Akaza","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.purol.2012.12.010_bib0115","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1\u00a0bladder cancer using EORTC risk tables: a combined analysis of 2596\u00a0patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?","volume":"146","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0125","first-page":"151","article-title":"Low dose BCG regimen in T1\u00a0transitional cell carcinoma of the bladder: long term results","volume":"21","author":"Kamel","year":"2009","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.purol.2012.12.010_bib0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1\u00a0bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0135","first-page":"1242","article-title":"La leucocyturie comme marqueur de la r\u00e9ponse th\u00e9rapeutique et des effets secondaires associ\u00e9s au traitement d\u2019entretien par instillations endo-v\u00e9sicales de BCG des tumeurs superficielles de vessie","volume":"11","author":"Saint","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-5347(17)43125-9","article-title":"Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial","volume":"138","author":"Hudson","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0145","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0022-5347(01)65674-X","article-title":"Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer","volume":"156","author":"Okamura","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0150","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0022-5347(17)42723-6","article-title":"Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer","volume":"139","author":"Torrence","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0155","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0022-5347(05)67025-5","article-title":"Elevated specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin","volume":"164","author":"Leibovici","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.12.010_bib0160","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2012.12.010_bib0165","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.purol.2012.12.010_bib0170","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.urology.2007.11.080","article-title":"Low-dose instillation therapy with bacille Calmette-Gu\u00e9rin Tokyo 172 strain after transurethral resection: historical cohort study","volume":"71","author":"Yoneyama","year":"2008","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.purol.2012.12.010_bib0175","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2012.12.010_bib0180","first-page":"206","article-title":"Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75\u00a0mg of Pasteur strain BCG","volume":"8","author":"Ayed","year":"1998","journal-title":"Prog Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708713000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708713000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:23:18Z","timestamp":1761114198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708713000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1166708713000067"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2012.12.010","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement d\u2019entretien par BCG-th\u00e9rapie des tumeurs de vessie n\u2019infiltrant pas le muscle (TVNIM)\u00a0: r\u00e9sultats \u00e0 un an de l\u2019\u00e9tude multicentrique URO-BCG-4","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2012.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}